He received his BSc (Microbiology and Clinical Laboratory Sciences) from Louisiana Tech University and his Ph.D. (Microbiology and Immunology) from LSU Health Science Center, Shreveport. Dr. Robertson has more than 20 years of classical and clinical microbiology experience with emphasis in antibacterial discovery and mode-of-action studies for novel and existing classes of antimicrobials. This includes efforts in academia, and also with larger pharmaceutical corporations (Eli Lilly and Co) and smaller bio-pharmaceutical groups (Cumbre Pharmaceuticals). His current research is focused on Mycobacterium tuberculosis host-pathogen interactions and the development and application of novel preclinical animal models to further anti-tuberculosis drug development and evaluate drug resistance.